SCHEMBL26276202

SCHEMBL26276202

CCCCCCCCOC(=O)[C@H](C)NP(=O)(OC[C@@]1(C#N)O[C@@H](c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ POLRMT O00411 1/20 0.39
▸ DOT1L Q8TEK3 1/20 0.33
▸ CYP3A4 P08684 2/20 0.32
▸ CYP2C9 P11712 2/20 0.32
▸ RIPK1 Q13546 1/20 0.31
▸ BTN3A1 O00481 4/20 0.31
▸ MEN1 O00255 1/20 0.30
▸ USP2 O75604 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ CASP1 P29466 1/20 0.30
▸ CASP7 P55210 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ NPSR1 Q6W5P4 1/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26276218 1.00 POLRMT (0.39) POLRMTDOT1LCYP3A4CYP2C9RIPK1
SCHEMBL26276211 1.00 POLRMT (0.39) POLRMTDOT1LCYP3A4CYP2C9RIPK1
SCHEMBL26276233 1.00 POLRMT (0.39) POLRMTDOT1LCYP3A4CYP2C9RIPK1
SCHEMBL26276210 1.00 POLRMT (0.39) POLRMTDOT1LCYP3A4CYP2C9RIPK1
SCHEMBL26286635 0.98 POLRMT (0.37) POLRMTDOT1LCYP3A4CYP2C9RIPK1
SCHEMBL30089943 0.97 POLRMT (0.40) POLRMTDOT1LCYP3A4CYP2C9RIPK1
SCHEMBL26275843 0.97 POLRMT (0.40) POLRMTDOT1LCYP3A4CYP2C9RIPK1
SCHEMBL26275829 0.95 POLRMT (0.40) POLRMTDOT1LCYP3A4CYP2C9RIPK1
SCHEMBL26275827 0.95 POLRMT (0.40) POLRMTDOT1LCYP3A4CYP2C9RIPK1
SCHEMBL26275831 0.95 POLRMT (0.40) POLRMTDOT1LCYP3A4CYP2C9RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109724-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2026-04-23 — — US disclosed
US-20230295201-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2023-09-21 — — US disclosed
US-20230295201-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2023-09-21 — — US disclosed
EP-4106877-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-12-28 — — EP disclosed
US-20220356196-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2022-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295201-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 POLRMT 535/4885DOT1L 3143/4885CYP3A4 435/4885
US-20220356196-A1 ANTIVIRAL COMPOUNDS MAVS, HAVCR2, ZC3HAV1 POLRMT 535/4885DOT1L 3143/4885CYP3A4 435/4885
US-20260109724-A1 ANTIVIRAL COMPOUNDS IRF3, IFNAR1, HAVCR2 POLRMT 1073/4885DOT1L 1953/4885CYP3A4 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback